Abstract
BackgroundThe detection of the Epstein–Barr capsid antigen (VCA) immunoglobulin A (IgA) is widely used in the diagnosis of nasopharyngeal carcinoma (NPC), but a reference standard for evaluating the presence of VCA-IgA is not yet available. Therefore, a reference standard is urgently needed for a uniform and quantitative detection of VCA-IgA.MethodsA mixed reference serum from three NPC patients diluted with healthy subject serum was made as a potential first international standard for VCA-IgA. VCA-IgA was detected in twenty NPC patients by four ELISA kits and two chemiluminescent immunoassays kits using the reference as a calibration curve. The performance of these six kits was evaluated, and the quantitative results were compared.ResultsOur results showed a good linearity of the reference in different kits. Without reference, the difference of the total coefficient of variation (from 3.98 to 43.11%) and Within-run coefficient of variation (from 2.47 to 19.66%) was large in the 6 kits. The positive and negative coincidence rate between the 6 kits and indirect immunofluorescence for NPC diagnosis was 75% overall agreement, but a difference among the six kits was found, ranging from 55 to 90%. The concentration of VCA-IgA in the 20 NPC samples led in the division into three categories such as negative, low, or medium/high positive, but these concentrations were significantly different within these three categories depending on the kit used of the 6 considered. However,a good correlation (R2 = 0.986) was observed between Antu and Beier ELISA kits.ConclusionsThe reference serum mightbe used as a reference standard for a better comparison of the results from different kits/laboratories. However, the quantitative results of some kits are still inconsistent due to the diversity of VCA antigens.
Highlights
Nasopharyngeal carcinoma (NPC) is highly endemic in South China
The reference serum mightbe used as a reference standard for a better comparison of the results from different kits/laboratories
VCAIgA antibody is usually measured by indirect immunofluorescence (IFA) [9] or enzyme-linked immunosorbent assay (ELISA) [10] with Indirect immunofluorescence (IFA) considered as the “gold standard”
Summary
Nasopharyngeal carcinoma (NPC) is highly endemic in South China. The ASIRW (age-standardized incidence rates of world) in South China (9.69/100,000) was 3.4 times higher than that in Southwest China (2.85/100, 000), which is the second in terms of incidence [1, 2]. EBV associated antibodies, such as virus capsid antigen (VCA-IgA) and Epstein-Barr virus nuclear antigen 1 (EBNA1-IgA), are used in the screening and diagnosis of NPC [4] and the former being one of the most widely used [5,6,7,8]. Thanks to the presence of enzyme-labeled antibodies instead of fluorescent antibodies, the immunoenzymatic assay (IEA) does not need a fluorescence microscope to interpret the results, which are semiquantitatively reported by the titers and are widely used in southern China [2, 3]. The detection of the Epstein–Barr capsid antigen (VCA) immunoglobulin A (IgA) is widely used in the diagnosis of nasopharyngeal carcinoma (NPC), but a reference standard for evaluating the presence of VCA-IgA is not yet available. A reference standard is urgently needed for a uniform and quantitative detection of VCA-IgA
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.